PULMATRIX, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PULMATRIX, INC. (PULM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $9.12 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-03-21
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was -$207.00K.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $8.98M.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $0.00.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $344.00K.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $9.12M.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.67M, a 0.95% decline from fiscal 2020.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $1.69M, a 39.08% increase from fiscal 2019.
- PULMATRIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $1.21M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $8.77M derived: sum of 2 quarters · filed 2025-03-21 | $8.77M derived: sum of 3 quarters · filed 2025-03-21 | $9.12M 10-K · filed 2025-03-21 |
| 2023-09-30 | $8.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $8.98M derived: sum of 2 quarters · filed 2024-11-08 | $9.32M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $344.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $344.00K 10-Q · filed 2024-05-10 | |||
| 2021-12-31 | $1.67M 10-K · filed 2023-03-30 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $1.69M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.69M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $1.69M 10-Q · filed 2020-08-07 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $0.00 derived: sum of 2 quarters · filed 2021-03-23 | $0.00 derived: sum of 3 quarters · filed 2021-03-23 | $1.21M 10-K · filed 2021-03-23 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $1.21M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.21M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $1.21M 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |